Subscribe To

Price Alert Latest News Economic Calendar News

IMGN / ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

ImmunoGen Inc. NASDAQ: IMGN is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver cancer-killing toxins to tumor cells while leaving healthy cells alone using antibodies that bind to antigens found on targeted cancer cells. Read More

Demo Live Account See Partner Details

Content Topics

Immunogen

Stock

Continues

Defy

Gravity

Phase

Trials

IMGN

Posted: Jun 26 2023, 08:13

Author Name: MarketBeat

IMGN News

By Zacks Investment Research
November 3, 2023

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The compan

By Seeking Alpha
October 31, 2023

Analyzing The Acquisition Potential Of ImmunoGen

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European

By Schaeffers Research
September 1, 2023

3 Examples of How Moneyness Impacts Options Trading

Subscribers to Chart of the Week received this commentary on Sunday, August 27.

By Seeking Alpha
August 29, 2023

ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuxi

By Market Watch
August 28, 2023

ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with

By Schaeffers Research
August 8, 2023

Options Bears Break Bank With Biotech Stock Puts

Subscribers to Schaeffer's Event Trader service scored a 272% profit with our ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation.

By Zacks Investment Research
July 31, 2023

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0

By Zacks Investment Research
July 17, 2023

ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors

ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke throug

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.